Upgrade to SI Premium - Free Trial

Karyopharm Therapeutics (KPTI)

7.18 -0.69 (8.77%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

RBC Capital on Karyopharm Therapeutics (KPTI): 'See Buying Oppty On Weakness' July 21, 2026 7:56 AM - StreetInsider Form 8-K Karyopharm Therapeutics For: Jul 13 July 17, 2026 5:01 PM - SEC Filing Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 1, 2026 4:05 PM - PR NewsWire H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI) June 18, 2026 6:48 AM - StreetInsider Karyopharm Therapeutics (KPTI) Reiterated at Overweight by Cantor Fitzgerald June 9, 2026 7:18 AM - StreetInsider Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc. June 5, 2026 11:43 AM - SEC Filing Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 June 3, 2026 4:15 PM - PR NewsWire Karyopharm cancer trial selected for late-breaking presentation at EHA June 2, 2026 10:03 AM - StreetInsider Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 June 2, 2026 10:03 AM - PR NewsWire Karyopharm presents phase 3 trial results at ASCO 2026 June 2, 2026 9:00 AM - StreetInsider Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of C June 2, 2026 9:00 AM - PR NewsWire Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 1, 2026 4:05 PM - PR NewsWire Karyopharm schedules investor call on myelofibrosis trial results June 1, 2026 7:30 AM - StreetInsider Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation June 1, 2026 7:30 AM - PR NewsWire Form 8-K Karyopharm Therapeutics For: May 21 May 28, 2026 5:01 PM - SEC Filing Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference May 28, 2026 7:30 AM - PR NewsWire Form S-8 Karyopharm Therapeutics May 27, 2026 5:00 PM - SEC Filing Form S-8 Karyopharm Therapeutics May 27, 2026 4:59 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Oliger Christy J. May 26, 2026 4:31 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: PAKIANATHAN DEEPIKA May 26, 2026 4:27 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Schor Chen May 26, 2026 4:25 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Su Zhen May 26, 2026 4:23 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: BOHLIN GAREN G May 26, 2026 4:20 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Greene Barry E May 26, 2026 4:15 PM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: Ikarian Capital, LLC May 15, 2026 5:04 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Poulton Stuart May 15, 2026 4:14 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Rangwala Reshma May 15, 2026 4:13 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Cheng Sohanya Roshan May 15, 2026 4:10 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Abate Kristin May 15, 2026 4:07 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Paulson Richard A. May 15, 2026 4:06 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Mano Michael May 15, 2026 4:05 PM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: ACORN BIOVENTURES, L.P. May 15, 2026 2:59 PM - SEC Filing Form EFFECT Karyopharm Therapeutics May 15, 2026 6:35 AM - SEC Filing Form EFFECT Karyopharm Therapeutics May 15, 2026 6:35 AM - SEC Filing Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Affinity Asset Advisors, LLC May 14, 2026 4:07 PM - SEC Filing Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 124c May 14, 2026 7:52 AM - StreetInsider Form 10-Q Karyopharm Therapeutics For: Mar 31 May 14, 2026 7:46 AM - SEC Filing Form 8-K Karyopharm Therapeutics For: May 14 May 14, 2026 7:32 AM - SEC Filing Karyopharm completes endometrial cancer trial enrollment, reports Q1 revenue May 14, 2026 7:30 AM - StreetInsider Karyopharm reports Q1 revenue up 17% as endometrial cancer study completes May 14, 2026 7:30 AM - StreetInsider Karyopharm completes endometrial cancer trial enrollment, reports Q1 results May 14, 2026 7:30 AM - StreetInsider Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment May 14, 2026 7:30 AM - PR NewsWire Form SCHEDULE 13G Karyopharm Therapeutics Filed by: Adage Capital Management, L.P. May 13, 2026 9:23 AM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: GOLDMAN SACHS GROUP INC May 12, 2026 3:58 PM - SEC Filing Intellia short interest rises most among biotech stocks in latest period - Baird May 12, 2026 9:58 AM - StreetInsider Karyopharm to Participate at Upcoming Investor Conferences May 12, 2026 7:30 AM - PR NewsWire Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Opaleye Management Inc. May 11, 2026 4:23 PM - SEC Filing Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 May 7, 2026 7:30 AM - PR NewsWire Karyopharm Therapeutics (KPTI) PT Raised to $13 at H.C. Wainwright May 6, 2026 7:04 AM - StreetInsider Karyopharm Therapeutics (KPTI) files for 8.84M share offering by selling stockholders May 4, 2026 4:41 PM - StreetInsider Karyopharm Therapeutics (KPTI) files $400M mixed shelf May 4, 2026 4:38 PM - StreetInsider Form S-3 Karyopharm Therapeutics May 4, 2026 4:38 PM - SEC Filing Form S-3 Karyopharm Therapeutics May 4, 2026 4:37 PM - SEC Filing Karyopharm Therapeutics (KPTI) PT Lowered to $8 at Piper Sandler April 27, 2026 9:36 AM - StreetInsider Full Article List